Controversies in Management of Localized Prostate Cancer: Before and After Radical Local Therapy

Abstract

Summary The therapeutic world of prostate cancer has evolved a lot in the last decade. Initially, we have only androgen deprivation therapies, earlier generation androgen receptor pathway inhibitor (ARPI), and chemotherapy. Now, we have multiple other options, and also there are ample data in all the spaces of its management. However, some areas need discussion, as controversies exist. In this review, we would like to throw some light on such controversial real in dealing with the biochemical recurrence after radical local therapy (RLT) and neoadjuvant treatment before RLT. We envisage to clear the cloud as per the existing literature.